Built upon our core 3D-EXplore platform, 3D-EXpress is a translational ex-vivo program designed to rapidly test immuno-oncology and oncology therapeutics using 3D tumoroids created from fresh patient tumors. Our tumoroids are never dissociated, propagated, or reassembled.
ISOLATION AND CHARACTERIZATION OF FRESH TUMOR TISSUE
CONVERSION INTO 3D TUMOROIDS
POOLING OF TUMOROIDS TO OVERCOME TUMOR HETEROGEINITY
ALIQUOTING OF TUMOROIDS AND CRYOPRESERVATION
EX VIVO TREATMENT OF PRESELECTED TUMOROIDS WITH CANDIDATE THERAPIES
WHAT IS 3D-EXPRESS?
Select pre-characterized tumors in our existing biorepository to generate actionable data by assessing target binding, stromal penetration and tumor cell killing of your drug and drug combinations using high content confocal imaging while analyzing conditioned media for cytokine release to monitor treatment-mediated changes in the tumor immune microenvironment.
Tumor Cell Killing
The tumor microenvironment consists of multiple cell types including tumor cells, immune cells and stroma. Nilogen's high-content 3D imaging system is capable of identifying tumor and non-tumor cells during our tumor killing assay and our proprietary analytics enables the quantitative analysis of cell killing in response to drug treatment.
Multiplex Cytokine Analysis
Cytokines including chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors, are all produced by a broad range of cell types. Cytokines have a specific effect on the behavior of neighboring cells by modulating maturation, growth, and the responsiveness of particular cell populations.